Drug intelligence / Profile preview

QN-05

Development stage: Preclinical
Lead developer: Qnovia
Modality: Peptides
Administration: Inhalation

Overview

QN-05 is a preclinical inhaled drug candidate developed by Qnovia in collaboration with the University of Virginia (UVA) for the treatment of pneumonia caused by bacterial lung infections. It utilizes Qnovia's RespiRx inhaled drug delivery platform to administer antimicrobial peptides from UVA's portfolio directly to the lungs. This drug aims to address the growing threat of multidrug-resistant bacteria and validate Qnovia's delivery technology in a new therapeutic area.

Beyond the preview

Go deeper on QN-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QN-05.

Explore the full profile